Antitrust and Regulatory Deal Risk

Both companies' boards can agree to a merger, shareholders can vote to approve it, financing can be lined up — and a regulator can still block it, because none of those parties get the final word on whether the deal is allowed to happen. Antitrust review exists specifically to stop combinations that would meaningfully reduce competition, and it is the single biggest source of deal risk that has nothing to do with whether the companies themselves want the deal to close.

What regulators are actually checking

Antitrust reviewers assess how much the merging companies compete with each other today, in specific, narrowly defined markets — not how big the combined company would be overall. Two companies with almost no product overlap can merge with minimal antitrust scrutiny even if both are huge; two mid-sized companies that are each other's closest competitor in one narrow product line can face serious antitrust risk even though the combined company isn't dominant industry-wide. The review typically has statutory waiting periods, during which the regulator can request more information (a "second request" that materially extends the timeline) or move to block the deal outright, sometimes requiring the parties to sell off overlapping business units (a "divestiture") as the price of approval.

Worked example

Two companies with the largest and third-largest market share in a specialized industrial product announce a $50 offer, and the stock trades to $46 — a wider-than-usual spread for a friendly, fully-financed cash deal. The desk's read: the deal is priced with real doubt not about financing or shareholder approval, but specifically about antitrust clearance, because the two companies compete head-to-head in a narrow, concentrated market segment. If the regulator ultimately requires a divestiture of the overlapping unit and clears the rest, the deal can still close near $50 — but if it's blocked outright, the stock could fall back toward its pre-announcement level near $35, a much larger downside than the $4 spread appears to compensate for at first glance.

What this means in practice

Antitrust risk explains why similarly "signed and financed" deals can trade at very different spreads: a desk has to assess market overlap and regulatory posture deal by deal, not assume all signed mergers carry the same completion odds. It also means deal timelines are genuinely uncertain — a clean deal can close in weeks, while one facing a second request can drag on for a year or more, tying up capital and shifting the trade's annualized return even if it eventually closes successfully.